Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of FAT1 and CASP8 inactivation

Tyler F. Hayes, Nathan Benaich, Stephen J. Goldie, Kalle Sipilä, Ashley Ames-Draycott, Wenjun Cai, Guangliang Yin, Fiona M. Watt

PII: S0304-3835(16)30556-0
DOI: 10.1016/j.canlet.2016.09.014
Reference: CAN 13037

To appear in: Cancer Letters

Received Date: 19 June 2016
Revised Date: 8 September 2016
Accepted Date: 8 September 2016

Please cite this article as: T.F. Hayes, N. Benaich, S.J. Goldie, K. Sipilä, A. Ames-Draycott, W. Cai, G. Yin, F.M. Watt, Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of FAT1 and CASP8 inactivation, Cancer Letters (2016), doi: 10.1016/j.canlet.2016.09.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of \textit{FAT1} and \textit{CASP8} inactivation

Tyler F. Hayes\textsuperscript{a}, Nathan Benaich\textsuperscript{a}, Stephen J. Goldie\textsuperscript{b}, Kalle Sipilä\textsuperscript{a}, Ashley Ames-Draycott\textsuperscript{a}, Wenjun Cai\textsuperscript{c}, Guangliang Yin\textsuperscript{c} and Fiona M. Watt\textsuperscript{a} *

\textsuperscript{a}Centre for Stem Cells and Regenerative Medicine, King’s College London, 28\textsuperscript{th} Floor, Tower Wing, Guy’s Hospital, London SE1 9RT, UK
\textsuperscript{b}Department of Medicine, Central Clinical School, Level 6, Alfred Centre, 99 Commercial Road, Melbourne VIC 3004, Australia
\textsuperscript{c}BGI-Shenzhen, Shenzhen 518038, China

*Correspondence to: Fiona.watt@kcl.ac.uk; +44-20-7188-5608

\textbf{Running title} Oral squamous cell carcinoma
Abstract

Oral squamous cell carcinoma (OSCC) is genetically highly heterogeneous, which contributes to the challenges of treatment. To create an in vitro model that accurately reflects this heterogeneity, we generated a panel of HPV-negative OSCC cell lines. By whole exome sequencing of the lines and matched patient blood samples, we demonstrate that the mutational spectrum of the lines is representative of primary OSCC in The Cancer Genome Atlas. We show that loss of function mutations in FAT1 (an atypical cadherin) and CASP8 (Caspase 8) frequently occur in the same tumour. OSCC cells with inactivating FAT1 mutations exhibited reduced intercellular adhesion. Knockdown of FAT1 and CASP8 individually or in combination in OSCC cells led to increased cell migration and clonal growth, resistance to Staurosporine-induced apoptosis and, in some cases, increased terminal differentiation. The OSCC lines thus represent a valuable resource for elucidating the impact of different mutations on tumour behaviour.

Keywords Oral squamous cell carcinoma, Caspase 8, FAT1, whole exome sequencing
1. Introduction

The global annual incidence of head and neck squamous cell carcinoma (HNSCC) is approximately 600,000, with over 300,000 deaths attributable to the disease each year (1). HNSCC lesions frequently recur and metastasize to other locations, contributing to significant morbidity and mortality (2). Despite improvements in surgical care and adjuvant therapy, the 5-year survival rate is only 60% in the United States (3).

Previous studies have used next-generation whole exome sequencing of primary tumours to reveal the mutational landscapes of human HNSCCs and suggest novel oncogenic drivers to target for potential therapies (4, 5, 6). HNSCC is strikingly heterogeneous at both the genetic and the cellular level. No single genetic lesion predominates and patients often develop more than one primary tumour.

Oral cancer is a subtype of HNSCC, comprising tumours of the lip and oral cavity. Worldwide, over 250,000 new cases and 125,000 deaths from oral cancer occurred in 2008 (1). Approximately 90% of oral cancers are squamous cell carcinomas (SCCs), arising in the multilayered epithelia that line the mouth and lips. Oral SCC (OSCC) frequently involves the tongue, and can also occur in the floor of the mouth, gingiva, cheek and palate. The two major risk factors for OSCC are smoking and alcohol consumption (7). In contrast to HNSCC of the tonsils and oropharynx, OSCC tends not to be associated with HPV infection (8, 9). Despite advances in treatment, the survival rate for OSCC remains stubbornly low (3).

As in other solid tumours (10, 11), the properties of the malignant epithelial cells in HNSCC elicit an immune infiltrate and activation of fibroblasts in the surrounding connective tissue stroma (1, 3, 12). Integrative analysis of the genetic and cellular heterogeneity of HNSCC is beginning to reveal new biologically distinct subtypes of the disease (13) and greater understanding of their
significance could inform future therapies. One way to achieve this is by studying the properties of cells isolated from HNSCC.

Cells can readily be cultured from human oral tumours and normal oral mucosa, and several well-annotated collections of HNSCC cells are available (14, 15, 16). However, genetic changes in individual cell lines have not been compared with control DNA from the original donors. Thus it has been difficult to discover whether the lines truly reflect the genetic heterogeneity of OSCC or are dominated by mutations acquired during long-term culture. The value of such lines lies in characterising the biology of genes that are frequently mutated in OSCC, including \textit{NOTCH1}, \textit{CASP8} (Caspase 8) and \textit{FAT1} (an atypical cadherin) (6), that are not conventional oncogenes/tumor suppressor genes and can potentially have pleiotropic effects on tumour properties. For example, the association between \textit{FAT1} mutation and overall survival in HNSCC differs according to the HPV status of the tumour (17) and loss of Caspase 8 not only has cell intrinsic effects (18) but can also trigger inflammation (19). Furthermore, there is evidence for biological interactions between \textit{FAT1} and Caspase 8, with \textit{FAT1} acting as an antagonist of Caspase 8 in a synthetic lethal screen in cancer cell lines (20).

In this study, we set out to develop new OSCC lines, discover which mutations are tumour-acquired and determine whether they are indeed representative of mutational burden in primary tumours. We then used the lines to explore the impact of mutations in \textit{CASP8} and \textit{FAT1} on cell behaviour.

2. Materials and Methods

2.1. Derivation of OSCC Lines Anonymized biopsies of OSCC or normal oral mucosa were collected with appropriate ethical approval (UK National Research Ethics Service (08/H0306/30).
Cells were isolated and cultured on a feeder layer of J2 3T3 cells in complete FAD medium as described previously (16).

2.2. Whole Exome Sequencing Genomic DNA was extracted from OSCC lines (passage 2-4) and patient-matched blood. Whole exome sequencing was performed by Beijing Genomics Institute (Hong Kong). Raw image files were processed by Illumina base calling Software 1.7 or base calling with default parameters, and the sequences of each individual were generated as 90 bp paired-end reads. High-quality reads were aligned against the NCBI human reference genome (hg19) using Burrows-Wheeler Aligner (v0.5.9) with default parameters. Picard (v1.54) was employed to mark duplicates and was followed by Genome Analysis Toolkit (v1.0.6076, GATK IndelRealigner) to improve alignment accuracy. Putative somatic SNV were predicted by VarScan2.25 with the parameters as “-- min-coverage 5 --min-coverage-normal 5 --min-coverage-tumour 5 --min-var-freq 0.1 --min-freq-for-hom 0.75 --min-avg-qual 0 —somatic-p-value 0.15”. In order to obtain high confidence somatic SNVs, an in-house pipeline was applied. Somatic InDels were predicted by GATK SomaticInDelDetector with default parameters. A pipeline was developed to obtain high confidence somatic InDels; normal and tumour bam were reused to perform local realignment and germline indels were filtered for high confidence indels, with normal coverage and tumour coverage no less than 5. High confidence somatic single nucleotide variants and InDels were annotated using ANNOVAR. Functional impacts of missense mutations were predicted using SIFT, PolyPhen2, PhyloP, MutationTaster and LRT annotations.

2.3. Prediction of driver genes and pathways The Oncodrive-fm method was applied, as previously published, to identify significantly mutant genes and KEGG pathways (21). Pathway enrichment analysis was also performed to identify additional significantly mutated KEGG pathways.
2.4. KEGG Pathway Analysis and Clustering Whole exome sequencing data from The Cancer Gene Atlas (TCGA) HNSCC collection (6) were accessed from cBioPortal.org. KEGG pathway analysis was performed, \(-\log_2(P)\) value were calculated and presented in heat maps created using GENE-E software (Broad Institute). OncoPrint, mutation diagrams and tests for mutual exclusivity of genomic alterations were downloaded from cBioPortal.

2.5. Quantitative real-time RT-PCR RNA was harvested using the RNeasy Mini Kit and QiAshredder columns according to manufacturer’s instructions (Qiagen). cDNA was synthesized using SuperScript™ III First-Strand Synthesis SuperMix (Invitrogen). qPCR was performed using TaqMan Fast Universal PCR Master Mix without AmpErase UNG (Life Technologies) on the CFX96 Touch Real-Time PCR Detection System (Bio-Rad) with the following primers: CASP8 (Hs01018151_m1), FAT1 (Hs00170627_m1) and GAPDH (Hs02758991_g1) as internal control (Life Technologies). Relative quantification was performed using the \(
\frac{1}{\Delta Ct}\) or \(\Delta\Delta Ct\) methods.

2.6. Transient transfection SMARTpool ON-TARGETplus CASP8 and FAT1 (GE Healthcare) and Silencer® Negative Control No.1 (Thermo Fisher) siRNAs were used. Prior to transfection, wells were coated with 20 \(\mu\)g/mL Rat Tail Collagen I (Corning) and incubated for 1 hour at 37°C. Cells were transfected using either Lipofectamine RNAiMax or Lipofectamine 2000 with Opti-MEM medium (Thermo Fisher). The viability of transfected cells was confirmed by Trypan Blue exclusion prior to performing cell behaviour assays.

2.7. Colony formation 48 hours after transfection, cells were seeded at clonal density in 6-well plates on a layer of feeders. 10-14 days after seeding, feeders were detached and keratinocytes were fixed in 10% formalin and stained with a solution of 1% Rhodamine B and 1% Nile blue.
Well images were acquired on the Gel Doc™ XR+ (Bio-Rad). Percent well area covered by cells was determined using the ColonyArea plugin (22) for ImageJ.

2.8. Cell Migration Assay
24 hours after transfection, cells were seeded on collagen-coated well plates in the Oris™ Cell Migration Assay (Platypus Technologies) and cultured in complete FAD medium. 24 hours after plating, cell seeding stoppers were removed. Phase-contrast images were acquired for 16-24 hours using an IncuCyte® ZOOM (Essen BioScience). Area closure was quantified in ImageJ, following the manufacturer’s instructions.

2.9. Induction of apoptosis
24 hours after transfection, cells were seeded on collagen-coated 96-well plates in complete FAD medium. 24 hours later cells were incubated with varying concentrations of Staurosporine (1285; Tocris) in complete FAD medium for 4 hours at 37°C.

2.10. Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde, permeabilized using 0.5% Triton X-100 (Sigma-Aldrich) in PBS and blocked in a solution of 10% fetal bovine serum (Thermo Fisher), 0.25% gelatin from cold water fish skin (Sigma-Aldrich) and 0.5% Triton X-100 in PBS. Cells were incubated overnight at 4°C with the following primary antibodies in blocking buffer: rabbit anti-Ki67 (1:50; ab16667; Abcam), Alexa Fluor® 488 conjugated anti-cleaved Caspase-3 (Asp175) antibody (1:50 in blocking buffer; 9669; Cell Signaling) or mouse anti-transglutaminase 1 (TG1; clone BC1; 1:500). Cells were incubated for 1 hour at room temperature in blocking buffer with the following secondary antibodies, as appropriate: Alexa Fluor® 488 goat anti-rabbit IgG H+L (1:1000; ab150077; Abcam) or Alexa Fluor® 555 goat anti-mouse IgG H+L (1:1000; ab150114; Abcam). Plasma membranes and nuclei were counterstained with CellMask™ Deep Red (1:1000 in PBS; C10046; Thermo Fisher) and DAPI (1 µg/mL in PBS), respectively, for 1 hour at room temperature. Following Caspase-3 labelling cell nuclei were counterstained with DRAQ5™ (5 µM in PBS; 108410; Abcam). Images were
acquired using the Operetta® High-Content Imaging System (PerkinElmer). Positive nuclear Ki67 and cytoplasmic TG1 immunostaining were quantified using an in-house pipeline on Harmony® software (PerkinElmer), while Caspase-3 positive cells were quantified using the “Apoptosis-1” module (PerkinElmer).

2.11. Statistical Analyses Data were analyzed using an unpaired Student’s t test or one-way ANOVA with Tukey’s Multiple Comparison Post Test on GraphPad Prism 5.0b, and a P value of < 0.05 was considered significant, unless otherwise noted.

3. Results

3.1. Whole exome sequencing of OSCC lines We derived multiple low passage polyclonal cell lines from primary oral squamous cell carcinoma biopsies by culture on a 3T3 J2 feeder layer in order to minimise selection for rapidly dividing cells (16). Whole exome sequencing was performed on 16 lines, together with patient-matched blood. We achieved 37- and 43-fold mean sequence coverage of targeted exonic regions, with 73 and 77% of loci covered at ≥ 20-fold from tumour and matched blood samples, respectively (Supplementary Figure S1). Mutation rates varied from 2.50 – 44.7 mutations/megabase (mean 16.9 ± 13.5), with 80 – 1431 somatic mutations per sample (mean 539 ± 432) (Figure 1A; Supplementary Table S1). A total of 8629 single nucleotide variations across 2611 genes were found, of which 5839 (68%) were synonymous, 2621 (30%) nonsynonymous, 125 (1.4%) stop-gains and 42 (0.49%) were splice-site mutations (Supplementary Table S2). Ninety-five insertions/deletions (indels) were found across 83 genes, of which 36 (43%) and 27 (32.5%) were non-frameshift and frameshift deletions, respectively. Thirteen (16%) and 19 (23%) were non-frameshift and frameshift insertions, respectively. The ratio of nucleotide transitions to transversions ranged from 1.17 – 3.00 (mean 2.24 ± 0.436) (Figure 1B). The frequency of C:G to A:T transversions and C:G to
T:A transitions varied inversely with mutation rate, while the frequency of T:A to C:G transitions increased with mutation rate.

Ten of the 16 cell lines were derived from cancers of the tongue, four from the alveolus, one from the buccal mucosa and one from the hard palate (Figure 1C; Supplementary Table S1). No associations were detected between self-described alcohol consumption, tobacco history or age, nor between mutation rate or differentiation status of the primary tumour. However, well-differentiated tumours tended to have a higher mutation rate than moderately differentiated tumours. All tumours were negative for common genotypes of human papilloma virus (HPV), determined by the absence of viral DNA integration in the sequenced exons.

To identify putative driver genes and pathways that, when mutated, contribute to OSCC tumourigenesis, the Oncogene-fm method was applied (21). We considered significant only those mutated genes or Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways with $Q$ values $< 0.10$. Only two genes were found to be significantly mutated – the canonical tumour suppressor $TP53$ ($p$-value $1.49 \times 10^{-9}$; $q$-value $3.72 \times 10^{-7}$) and $CSMD2$ (CUB and sushi domain-containing protein 2; $p$-value 0.00024; $q$-value 0.03013). While $CSMD2$ has a tumour suppressive role in several cancers (23, 24), $CSMD2$ mutations in HNSCC have not been described previously.

Twenty KEGG pathways were significantly mutated across the 16 OSCC lines (Supplementary Table S3). Unsurprisingly, ten were pathways for specific cancers and three for other human diseases profiled in KEGG. Three cellular community pathways (Adherens Junction, Focal Adhesion and Tight Junction) and two signaling pathways (Wnt and B Cell Receptor Signaling Pathways) were also significantly mutated. Pathway enrichment analysis was performed in parallel, and seven KEGG pathways were significantly mutated with a corrected $P$ value $< 0.10$
(Supplementary Table S4). Common pathways identified by both methods were Focal Adhesion and Wnt Signaling. The contribution of upregulated Wnt/β-catenin signaling to cell survival and invasion in HNSCC has been previously discussed (15, 25, 26). Recent work suggests that transcriptional regulation of focal adhesion genes plays a crucial role in OSCC pathogenesis and that focal adhesion kinase (FAK) is a key mediator of extra-cellular matrix interactions and cellular signaling contributing to HNSCC onset and progression (27, 28).

In 2015, The Cancer Gene Atlas (TCGA) Network published genomic profiles for 279 HNSCCs (6). Of the 11 genes identified in that study as significantly mutated and eight trending towards significance, nine and five, respectively, were identified as harboring somatic mutations across 13 of our 16 cell lines (Figure 1D). These include inactivating NOTCH1 mutations (found in 10-15% of HNSCC) (4, 5, 6), which cluster to the EGF-like binding domain and domains necessary for transactivation of target genes. Tumour-associated NOTCH1 mutations were identified in three of our OSCC lines via whole exome sequencing (Figure 1D). In addition, Sanger sequencing of the entire genomic region of NOTCH1-3 was performed on all OSCC lines, including lines for which matched blood was not available. This identified several additional novel bona fide somatic (nonsynonymous, nonsense and indel) mutations (Supplementary Figure 2). 44% of the cell lines contained mutations in NOTCH1, many of the mutations clustering in the EGF-like domain. Mutations in NOTCH2 and 3 were less common. The presence of mutations in the PEST domain of NOTCH3 could potentially result in increased receptor activity due to decreased ubiquitin-mediated degradation.

3.2. OSCC lines are representative of primary tumour heterogeneity To discover whether the mutational spectrum of OSCC is distinct from that of other HNSCCs, we determined the site of origin of each of 267 tumours in TCGA and then performed unsupervised clustering of the samples according to the significance of mutated KEGG pathways (Figure 1E). This indicated
that the spectrum of KEGG pathways mutated in OSCC were similar to those of HNSCC arising in other sites.

To determine whether the KEGG pathways that were mutated in the OSCC lines were similar to those in primary tumours, we performed unsupervised clustering of TCGA OSCC samples ranked according to the frequency of mutated KEGG pathways in the cell lines. As shown in Figure 1F, the pathways that were mutated in the lines were indeed representative of those in primary tumours.

3.3. Mutations in CASP8 and FAT1 To evaluate the impact of mutations and expression of putative driver genes established by genomic studies on OSCC cell behaviour, we conducted a systematic literature review of genes implicated in homeostasis or disease in stratified squamous epithelia through regulation of adhesion, invasion or motility. We focused on genes that were members of multiple mutated non-tissue specific KEGG pathways and/or were most significantly mutated in our study and TCGA. We prioritized those genes harbouring mutations in more than 8% of HNSCCs and at least two of our cell lines. Seven genes were identified – PLEC, CASP8, SYNE2, FAT1, LRP1B, COL11A1 and HUWE1 (Figure 2A). We also queried TCGA for pair associations of mutations across these genes in HNSCC (Figure 2B). CASP8 and FAT1 (P value = 0.0003), and SYNE2 and LRP1B (P value = 0.015) were identified as frequently co-mutated in HNSCC.

Of the 279 patients with HNSCC reported by TCGA in 2015 (6), 172 patients had tumors of the oral cavity and the other 107 had tumors of the oropharynx (n = 33), hypopharynx (n =2) and larynx (n = 72). Considering copy number alterations and truncating, missense and in-frame mutations, 23% of tumors of the oral cavity harbored mutations in FAT1 alone, 5.8% in CASP8 alone and 9.3% in both FAT1 and CASP8, compared with 22%, 2.8% and 1.9%, respectively, in
tumors of other areas of the head and neck. The increased frequency of CASP8 and FAT1 co-
mutations in OSCC relative to other HNSCC, recent evidence suggesting functions of CASP8
that extend beyond programmed cell death (29), and uncertainty surrounding the role of FAT1 in
oncogenesis (30) led us to focus on these two genes.

Whole exome sequencing revealed eight putative inactivating somatic mutations in FAT1 across
four of the 16 OSCC lines, and three in CASP8 across three lines (Figure 2C). Inactivating
mutations were defined as frameshift indels, and splice-site, nonsense and missense mutations
predicted to be deleterious to protein function by ANNOVAR. Two lines simultaneously harbored
mutations in both FAT1 and CASP8. Similar to the gene span of inactivating mutations in TCGA,
mutations in FAT1 and CASP8 did not localize to any particular protein domain.

We next determined mRNA levels of CASP8 and FAT1 in OSCC cell lines by Q-PCR (Figure
2D). There was no significant difference between CASP8 levels in wild type and mutant lines,
nor between OSCC cells and normal oral keratinocytes. However, there was a trend for lower
FAT1 mRNA levels in FAT1 mutant lines compared to wild type (P value < 0.05). In addition,
FAT1 mRNA levels were higher in normal oral keratinocytes than OSCC lines (Figure 2D).
These observations were consistent with primary tumour data from TCGA, since CASP8 mRNA
levels in tumours with mutant CASP8 did not differ from those with wild type CASP8 at a given
copy number, whereas there was a trend to lower FAT1 mRNA levels in tumours bearing FAT1
mutations (Figure 2E).

3.4. Phenotypic effects of loss or inactivation of CASP8 and FAT1 To characterise the
effect of FAT1 mutations on OSCC lines we first observed the morphology of cells grown on
feeders. As shown in Figure 3A, cells with FAT1 mutations tended to form less cohesive
colonies than cells that were wild type for FAT1. However, FAT1 knockdown in SJG-33 cells,
which are wild type for FAT1, was not sufficient to reduce cell-cell adhesion (Figure 3A, B). We also observed that the level of FAT1 mRNA increased with increased cell density in cells with wild type but not mutant FAT1 (Figure 3B). This did not correlate with the level of FAT1 mRNA in cells at low density and was more marked in OSCC lines than in control oral keratinocytes.

To determine the impact of FAT1 expression on the growth of OSCC cells in culture, we performed siRNA-mediated knockdown in cells with wild type FAT1 (Supplementary Figure 3A) and then compared clonal growth with cells expressing scrambled control siRNA (Figure 3C, D; Supplementary Figure 3B). We also examined cells in which we knocked down CASP8, alone or in combination with FAT1 knockdown. We observed that knockdown of each gene, alone or in combination, stimulated clonal growth of OSCC in culture but had no effect on the growth of primary oral keratinocytes.

Given the association between FAT1 mutation and cell-cell adhesion (Figure 3A) and between CASP8 and integrin-mediated cell migration (29), we next examined the effect of knockdown on cell migration. We monitored the ability of cells to migrate into a circular area exposed in the centre of the culture dish during a 24h period. In the case of mutant cells, there were frequent individual cells that had migrated into the area independently of the migrating epithelial front (Figure 3E). Quantitation of the assays showed that knockdown of FAT1 or CASP8 alone and in combination increased cell migration in OSCC but not in primary keratinocytes (Figure 3F). In some cases the effect of CASP8 knockdown was greater than that of FAT1 (e.g. SJG-8, SJG-32, which harbor FAT1 mutations), whereas in others knockdown of CASP8 and FAT1 individually or in combination were equally effective (SJG-6, SJG-17).

The impact of CASP8 and FAT1 knockdown on clonal growth could not be accounted for by an increase in proliferation, and in several cases Ki67 labelling was, rather, reduced (Figure 4A).
Knockdown of *CASP8* and *FAT1* did not have a consistent effect on the proportion of cells that underwent terminal differentiation, as judged by the percentage of cells expressing Transglutaminase 1: there was no effect of double knockdown on SJG-17 cells; differentiation was stimulated in SJG-33 cells; and decreased in SJG-41 cells (Figure 4B). Knockdown of *CASP8* and *FAT1* did, however, increase resistance to Staurosporine-induced apoptosis (Supplementary Figure 4), as judged by Caspase-3 immunostaining (Figure 4C).

We conclude that loss of function mutations in *CASP8* and *FAT1* are likely to confer a growth advantage on OSCC by reducing cell-cell adhesion, promoting cell migration and conferring resistance to apoptosis. Furthermore, as expected, knockdown tended to have more pronounced effects in cells with wild type *CASP8* and *FAT1*.

4. Discussion

While many investigators have generated cell lines from human HNSCC and used them to study the biology of this tumour type (14, 15, 16), our study is the first to derive cell lines for which matching normal patient DNA is available. Furthermore, we demonstrate that the spectrum of tumour-acquired mutations is representative of that found in tumour biopsies, for example in the case of *NOTCH1-3* (6, 15). These lines will be of considerable value for studying tumour cell behaviour *in vitro* and in xenograft assays.

As proof of the utility of the lines, we studied the impact of loss of functional *CASP8* and *FAT1*, two genetic changes that, we found, frequently occur together in individual OSCC. We found that in the lines, as in primary tumours, inactivating mutations in *CASP8* did not result in a reduction in *CASP8* expression, whereas *FAT1* mutation did correlate with reduced mRNA levels. While *FAT1* mutant lines showed reduced intercellular adhesion, *FAT1* knockdown in a wild type line was not sufficient to cause a significant change in morphology. It will therefore be
of interest to discover whether the effect of FAT1 loss is dependent on other OSCC mutations (Figure 1D). For example, mutations in PTEN will affect the actin cytoskeleton (31) and AJUBA mutations are likely to impact E-cadherin mediated cell adhesion (32). Furthermore, although we have not explored the underlying mechanism by which FAT1 mRNA levels increase in some cell lines with increasing cell density but not in others (Figure 3B), this has the potential to affect cell behaviour via an impact on HIPPO signalling (30).

Knockdown of each gene in cells that were wild type for \textit{CASp8} and \textit{FAT1} confirmed a clonal growth advantage, consistent with the observation that \textit{CASp8} mutant cells are more aggressive in tongue xenografts (15). This could be attributed, at least in part, to increased cell migration and reduced apoptosis, rather than to an increase in the proportion of actively cycling cells. The consequences of stimulation of terminal differentiation, observed in some cells, remain to be explored but could potentially lead to increased release of cytokines such as IL-6 that render the microenvironment permissive for tumour growth (31) and altered inflammatory signalling in CASP8 mutant cells (19). Cells that show a more pronounced phenotype on combined knockdown of CAS8 and FAT1 will be useful for exploring the cancer relevance of the observed antagonistic interactions between FAT1 and Caspase 8 (20).

In conclusion, OSCC is highly heterogeneous at both the cellular and genetic levels. The panel of cell lines that we have characterised will be useful for identifying the signalling pathways that are affected by particular combinations of mutations and for discovering how they act both at the level of the cells that bear the mutations and at the level of the surrounding stroma and immune infiltrate. In the long term, this type of approach has the potential to suggest new combination therapies to improve the outcome for patients with OSCC.

5. Acknowledgements
This work was supported by the UK Medical Research Council [G1100073], the Wellcome Trust [096540/Z/11/Z] and the UK Regenerative Medicine Platform. We gratefully acknowledge use of Core Facilities provided by the financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust. We thank Richard Price, Samuel Woodhouse, Gernot Walko, Kifayathullah Liakath-Ali, Ajay Mishra, Giacomo Donati, Kazunori Sunadome and Simon Broad for their helpful input. The authors have no competing interests to declare.
References

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127: 2893–2917.

2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. *Lancet* 2008; 371:1695-1709.

3. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. *Nat Rev Cancer* 2011;11: 9-22.

4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* 2011; 333:1154-1157.

5. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al. The mutational landscape of head and neck squamous cell carcinoma. *Science* 2011; 333: 1157-1160.

6. TCGA. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015; 517: 576-582.

7. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *JNCI* 2007; 99: 777–789.
8. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* 2007; **356**:1944-1956.

9. Nygård M, Aagnes B, Bray F, Møller B, Mork J. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. *Eur J Cancer* 2012; **48**:1341-1346.

10. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. *Dev Cell*. 2010; **18**:884-901.

11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; **14**:646-674.

12. Wallis SP, Stafford ND, Greenman J. Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers. Head Neck 2015; **37**:449-459.

13. Keck MK, Zuo Z, Khattri A, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. *Clinical Cancer Research* 2015; **21**:870-881.

14. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumour sites. *Clin Cancer Res* 2011; **17**: 7248-7264.
15. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. *Cancer Discov* 2013; 3:770-781.

16. Goldie SJ, Mulder KW, Tan DW, Lyons SK, Sims AH, Watt FM. FRMD4A upregulation in human squamous cell carcinoma promotes tumour growth and metastasis and is associated with poor prognosis. *Cancer Res* 2012; 72: 3424-3436.

17. Kim KT, Kim BS, Kim JH. Association between FAT1 mutation and overall survival in patients with human papillomavirus-negative head and neck squamous cell carcinoma. *Head Neck*. 2016; 38 Suppl 1:E2021-9.

18. Galluzzi L, López-Soto A, Kumar S, Kroemer G. Caspases connect cell-death signaling to organismal homeostasis. *Immunity* 2016; 44:221-231.

19. Kovalenko A, Kim JC, Kang TB, et al (2009) Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. *J Exp Med*. 2009; 206:2161-2177.

20. Kranz D, Boutros M. A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. *EMBO J*. 2014; 33:181-197.

21. Gonzalez-Perez A, Lopez-Bigas, N. Functional impact bias reveals cancer drivers. *Nucl Acids Res* 2012; 40: e169.

22. Guzmán C, Bagga M, Kaur A, Westermark J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. *PLoS ONE* 2014; 9: e92444.
23. Zhang R, Song C. Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. *Tumour Biol* 2014; **35**: 4419–4423.

24. Iwakawa R, Kohno T, Totoki Y, Shibata T, Tsuchihara K, Mimaki S *et al.* Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. *Carcinogenesis* 2015; **36**: 616–621.

25. Yang F, Zeng Q, Yu G, Li S, Wang C-Y. Wnt/β-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. *Cellular Signalling* 2006; **18**: 679–687.

26. Goto M, Mitra RS, Liu M, Lee J, Henson BS, Carey T *et al.* Rap1 stabilizes β-Catenin and enhances β-Catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. *Clinical Cancer Res* 2009; **16**: 65–76.

27. Canel M, Secades P, Rodrigo JP, Cabanillas R, Herrero A, Suarez C, *et al.* Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is Independent of fak gene copy number. *Clin Cancer Res* 2006; **12**: 3272–3279.

28. He Y, Shao F, Pi W, Shi C, Chen Y, Gong D *et al.* Largescale transcriptomics analysis suggests over-expression of BGH3, MMP9 and PDIA3 in oral squamous cell carcinoma. *PLoS ONE* 2016; **11**: e0146530.

29. Graf RP, Keller N, Barbero S, Stupack D. Caspase-8 as a regulator of tumour cell motility. *Curr Mol Med* 2014; **14**: 246-254.
30. Sadeqzadeh E, de Bock CE, Thorne RF. Sleeping giants: emerging roles for the fat cadherins in health and disease. *Med Res Rev* 2014; 34: 190-221.

31. Vitolo MI, Boggs AE, Whipple RA, et al. Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin. *Oncogene* 2013; 32:2200-2210.

32. Nola S, Daigaku R, Smolarczyk K, et al. Ajuba is required for Rac activation and maintenance of E-cadherin adhesion. *J Cell Biol*. 2011;195:855-871.

33. Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer. *Nat Rev Cancer* 2012; 12: 170-180.

**Figure Legends**

**Fig. 1. Genomic analysis of OSCC lines and TCGA HNSCC tumours.** A-C) Somatic mutation rates (A), nucleotides transition and transversion frequencies (B), clinical characteristics and social histories (C) of cell lines and patients from which they were derived. D) Somatic single nucleotide variants (SNVs) and insertion/deletions (indels) in significantly mutated genes. Genes are ranked in order of significance from TCGA (6). E) Unsupervised clustering of TCGA HNSCC samples according to significance of mutated KEGG pathways. Rows are individual tumours; columns are KEGG pathways. OSCC are shown separately from other HNSCC. F) Unsupervised clustering of TCGA OSCC samples ranked according to frequency of mutated KEGG pathways (descending rank order) in OSCC cell lines. Rows are pathways and columns are individual tumours. (E, F) Color scale is based on $-\log_2(P)$ values.
Fig 2. Identification of CASP8 and FAT1 as putative HNSCC/OSCC drivers. A) Genetic alterations in putative driver genes identified by exomic sequencing and literature review. Samples are arranged to emphasize mutual exclusivity among mutations. Samples without genetic alterations in these genes are not shown. B) Pair associations of genetic alterations among putative driver genes in TCGA HNSCC project. P value was determined by Fisher’s Exact test. C.O. = co-occurrence, M.E. = mutually exclusive. C) Genetic alterations in CASP8 and FAT1 in TCGA HNSCC and OSCC cell line datasets. LAGD = laminin a-g domain; EGFLR = EGF-like repeat; asterisk indicates mutation present in both TCGA and cell line datasets. D) mRNA expression of CASP8 and FAT1 in OSCC cell lines. P value was determined by unpaired Student’s t-test. *P < 0.01 – 0.05. No significant difference was detected between presence of CASP8 mutations and CASP8 mRNA expression. OK and CRI-005 are two strains of primary oral keratinocytes. mut = mutant, wt = wild type. E) CASP8 mRNA levels in tumours with mutant and wild type CASP8 (right hand panel) and FAT1 mRNA levels in tumours with mutant and wild type FAT1 (left hand panel) stratified by putative copy-number alterations. Data from TCGA (6).

Fig. 3. Phenotypic impact of CASP8 and FAT1 mutations and siRNA knockdown in OSCC lines. A) Phase-contrast microscopy of OSCC lines with (mt) and without (wt) predicted inactivating mutations in FAT1, and effects of FAT1 siRNA on SJG-33 (wt for FAT1). B) FAT1 mRNA expression in OSCC lines plated at low and high density for 48-72 hours. OK = primary oral keratinocytes. C, D) Impact of CASP8 and FAT1 knockdown on clonal growth. (C) Triplicate dishes of SJG-17 cells. (D) Percent well area covered by cell clones. Significant differences from non-targeting control siRNA (siSCR) are shown. A-D) Cells were cultured on feeders. E, F) Impact of CASP8 and FAT1 knockdown on cell migration. (E) Representative images of cells at start (0h) or 24h later. In high magnification view, arrow indicates migratory cell front; asterisks indicate individual migrating cells. (F) Migration rate, defined as fold change in area of central detection zone at 16 – 24 hours. Data are presented as mean ± SEM. (E, F) Cells were plated
in the absence of feeders. (D, F) P values were determined by ANOVA and Tukey’s test. *P < 0.01 – 0.05, **P < 0.001 – 0.01, ***P < 0.0001 – 0.001.

Fig. 4. Impact of CASP8 and FAT1 siRNA knockdown on proliferation, differentiation and apoptosis. A) Proliferation was assessed by Ki67 immunostaining. Significant differences from non-targeting control siRNA (siSCR) are shown. wt = wild type, mut = mutant, OK = primary oral keratinocytes. B) Terminal differentiation was assessed by transglutaminase 1 (TGM1) immunostaining. A, B) Plasma membranes and nuclei were counterstained with CellMask™ Deep Red and DAPI. C) Cells were incubated with Staurosporine, and apoptosis was measured by Caspase-3 (CASP3) immunostaining. (A-C) Representative images are shown for SJG-33 (A), control O.K. and SJG-6 (B), siCASP8 and siCASP8/FAT1 SJG-41 (B) and SJG-17 (C). Data are presented as mean ± SEM. P value was determined by ANOVA and Tukey’s test. *P < 0.01 – 0.05, **P < 0.001 – 0.01, ***P < 0.0001 – 0.001. Scale bars 100 µm.
Supplementary Table S1: Clinical and genomic information for OSCC patient-derived cell lines. Alcohol and smoking histories were self-reported. All other information was reported by the patient’s providers. Statistics listed are for somatic mutations. Alcohol: No = does not drink, Minimal ≤ 1 drink per day for women or 2 drinks for men, Moderate = 5-7 drinks per week for women or 10-14 drinks for men, Heavy ≥ 8 drinks per week for women or 15 for men. Anatomical site: RMT = retromolar trigone. Differentiation: describes tumor biopsy from which lines were derived. Mb = megabase.

Supplementary Table S2: Somatic mutations in OSCC lines. Mutations presented were detected by whole exome sequencing and annotated using ANNOVAR.

Supplementary Tables S3-4: Significantly mutated pathways in OSCC lines. Mutated KEGG pathways were identified using (S3) the Oncodrive-fm method (Gonzalez-Perez & Lopez-Bigas, 2012) or (S4) via pathway enrichment analysis.

Supplementary Figure S1: Whole exome sequencing coverage and depth. A) Distribution of coverage. Box-and-whisker plots display the average percentage of targeted bases at various fold-coverages across 16 tumor-derived cell lines (T) and normal patient-matched blood (N). B) Distribution of depth. Box-and-whisker plots display the average sequencing depth across all targeted regions.

Supplementary Figure S2: Sanger sequencing of OSCC lines identifies novel mutations in NOTCH1-3. Numbers represent tissue ID of cell lines, including those for which patient-matched blood was not available. Triangles represent localization of mutation in protein. N\text{ECD} = Notch extracellular domain, N\text{TMIC} = Notch transmembrane and intracellular domain, EGF = epidermal growth factor-like repeats, NRR = negative regulatory region, LNR = Lin-12/Notch repeats, HD = heterodimerization domain, TMD = transmembrane domain, RAM = Rbp-associated molecule domain, ANK = ankyrin repeat domain, PEST = proline, glutamic acid, serine and threonine sequence.

Supplementary Figure S3: A, B) siRNA knockdown efficiency. Quantitative real-time RT-PCR was performed on transcripts harvested 48 hours after transfection. LF = Lipofectamine. (B) SJG-33 cells. C) Representative colony formation assays.
Supplementary Figure S4: Staurosporine-induced apoptosis assay. A) Representative images of SJG-6 cells treated with varying concentrations of Staurosporine for 4 hours in complete FAD medium and stained for active Caspase-3. B-C) Dose response curves for Staurosporine treatment (B) using positive Caspase-3 as a readout for apoptotic cells and (C) measuring nuclear fragmentation index and mean nucleus area with the “Apoptosis-1” module on Harmony software. Scale bars 100 µm.

Reference
Gonzalez-Perez A, Lopez-Bigas, N. Functional impact bias reveals cancer drivers. Nucleic Acids Res 2012;40:e169.
Figure 1

A

B

C

D

E

F

A. Bar graph showing the number of mutations per Mb across different samples.

B. Heatmap illustrating the percentage of mutations across various samples.

C. Heatmap showing the differentiation and alcohol consumption across different samples.

D. Heatmap depicting the expression levels of various genes across different samples.

E. Heatmap indicating the global distribution of mutations.

F. Heatmap showing the distribution of mutations in the Oral Cavity and Other Head & Neck regions.

Legend:
- **CDKN2A**, **FA**, **TP53**, **CASP8**, **AJUBA**, **PIK3CA**, **NOTCH1**, **MLL2**, **NSD1**, **HRAS**, **FBXW7**, **NFE2L2**, **CUL3**, **PTEN**
- Synonymous
- Missense
- Splice site
- Frameshift
- Nonsense
- In-frame indel

Cancer site:
- Tongue
- Alveolus
- Other

Differentiation:
- Poor
- Moderate
- Well

Alcohol:
- Yes
- No

<60y:
- Yes
- No

Tobacco:
- Yes
- No
Figure 2

A

Genetic Alteration

| Gene     | %     |
|----------|-------|
| PLEC     | 18%   |
| CASP8    | 11%   |
| SYNE2    | 9%    |
| FAT1     | 29%   |
| LRP1B    | 20%   |
| COL11A1  | 11%   |
| HUWE1    | 13%   |

B

| Gene A | Gene B | p-value | Log Odds Ratio | Association |
|--------|--------|---------|----------------|-------------|
| CASP8  | FAT1   | 0.00032345 | 1.4026435 | C.O.         |
| SYNE2  | LRP1B  | 0.01529065 | 1.0771061 | C.O.         |
| PLEC   | CASP8  | 0.05521899 | -1.247032 | M.E.         |
| FAT1   | COL11A1| 0.05641717 | 0.7107253 | C.O.         |
| LRP1B  | COL11A1| 0.05804411 | 0.7649729 | C.O.         |

C

D

E

mRNA expression (log2)

E

mRNA expression (log2)
Figure 3

A  

SJG-6  SJG-8  SJG-18  

FAT1mut  FAT1wt  FAT1 knockdown  

SJG-13  SJG-17  O.K.  

SJG-33 wt  SJG-33 Scr siRNA  SJG-33 Fat1 siRNA  

B  

fold change FAT1 expression normalized to siSCR  

SJG-8  SJG-32  SJG-6  SJG-18  SJG-13  SJG-17  SJG-33  SJG-41  O.K.  

FAT1mut  CASP8/FAT1wt  

C  

siSCR  siCASP8  siFAT1  siCASP8/FAT1  

D  

area covered by cells (%)  

FAT1mut  CASP8mut  CASP8/FAT1wt  

E  

FAT1  siCASP8/FAT1  CASP8  

F  

fold change migration rate normalized to siSCR  

FAT1mut  CASP8mut  CASP8/FAT1wt  

SJG-6  SJG-8  SJG-18  SJG-33  O.K.  

FAT1mut  CASP8mut  CASP8/FAT1wt  

siCASP8  siFAT1  siCASP8/FAT1  

SJG-8  SJG-32  SJG-6  SJG-18  SJG-13  SJG-17  SJG-33  SJG-41  O.K.
Figure 4

A

% nuclei Ki67 positive

\[
\begin{array}{|c|c|c|c|c|c|c|c|}
\hline
\text{Cell Line} & \text{siSCR} & \text{siCASP8} & \text{siFAT1} & \text{siCASP8/FAT1} & \text{wt} & \text{FAT1mut} \\
\hline
\text{SJG-33} & O.K. & & & & & \\
\hline
\text{SJG-6} & & & & & & \\
\hline
\text{SJG-18} & & & & & & \\
\hline
\text{SJG-13} & & & & & & \\
\hline
\text{SJG-17} & & & & & & \\
\hline
\text{SJG-33} & & & & & & \\
\hline
\text{SJG-41} & & & & & & \\
\hline
\text{O.K.} & & & & & & \\
\hline
\end{array}
\]

B

% cells TGM1 positive

\[
\begin{array}{|c|c|c|c|c|c|c|}
\hline
\text{Cell Line} & \text{siSCR} & \text{siCASP8} & \text{siFAT1} & \text{siCASP8/FAT1} & \text{wt} & \text{FAT1mut} \\
\hline
\text{SJG-33} & O.K. & & & & & \\
\hline
\text{SJG-6} & & & & & & \\
\hline
\text{SJG-18} & & & & & & \\
\hline
\text{SJG-13} & & & & & & \\
\hline
\text{SJG-17} & & & & & & \\
\hline
\text{SJG-33} & & & & & & \\
\hline
\text{SJG-41} & & & & & & \\
\hline
\text{O.K.} & & & & & & \\
\hline
\end{array}
\]

C

% apoptotic cells

\[
\begin{array}{|c|c|c|c|c|c|c|}
\hline
\text{Cell Line} & \text{0 µM} & \text{1 µM} & \text{5 µM} & \text{0 µM} & \text{1 µM} & \text{5 µM} \\
\hline
\text{SJG-17} & & & & & & \\
\hline
\text{SJG-18} & & & & & & \\
\hline
\end{array}
\]

staurosporine

\[
\begin{array}{|c|c|c|c|c|c|c|}
\hline
\text{Cell Line} & \text{0 µM} & \text{1 µM} & \text{5 µM} & \text{0 µM} & \text{1 µM} & \text{5 µM} \\
\hline
\text{SJG-17} & & & & & & \\
\hline
\text{SJG-18} & & & & & & \\
\hline
\end{array}
\]
Highlights

- Generation of human oral squamous cell carcinoma lines with whole exome sequence data
- Mutational spectrum of the lines is representative of primary tumours
- Loss of function mutations in FAT1 and CASP8 frequently co-occur
- Inactivating FAT1 mutations correlate with reduced intercellular adhesion
- Inactivation of FAT1 and CASP8 results in increased clonal growth, migration and apoptosis resistance